Intestinal microbiome: a new target for chalaziosis treatment in children?

  • Home
  • /
  • Intestinal microbiome: a new target for chalaziosis treatment in children?

Intestinal microbiome: a new target for chalaziosis treatment in children?

What is Known:
• The intestinal microbiome plays a crucial role in several inflammatory diseases of the eye and is considered a therapeutic target.
• Probiotics play a role in the prevention and treatment of different conditions in children.

What is New:
• In children probiotic supplementation is safe and effective.
• Probiotic supplementation reduced the time required for complete resolution of the chalazion.

Intestinal microbiome: a new target for chalaziosis treatment in children?

Published: 23 November 2020

Mariaelena Filippelli, Roberto dell’Omo, […]Ciro Costagliola
European Journal of Pediatrics (2020)

Intestinal dysbiosis (changes in the gut commensal microbiome) is related to several ophthalmic diseases. The aim of this study was to verify whether oral specific probiotics can alter the clinical course of chalaziosis and its recurrence.

A prospective comparative pilot study involving 26 children suffering from chalaziosis was conducted. Children were randomly divided into two groups. The first group received medical treatment (lid hygiene, warm compression and dexamethasone/tobramycin ointment for at least 20 days), and the second group received medical treatment plus a daily supplementation of oral probiotics (≥ 1 × 10^9 live cells of Streptococcus thermophilus ST10 (DSM 25246), ≥ 1 × 10^9 live cells of Lactococcus lactis LCC02 (DSM 29536) and ≥ 1 × 10^9 live cells of Lactobacillus delbrueckii subsp. bulgaricus (DSM 16606) with maltodextrin as the bulking agent (Probiotical S.p.A., Novara, Italy).

All patients were evaluated at 2-week intervals for 3 months. If the lesion had not disappeared or decreased in size to 1 mm or less in diameter at the time of subsequent visits, the same procedure was repeated for another 3-month cycle. There was a significant difference in the time taken for complete resolution of the chalazion between the two groups in favour of the children receiving the probiotics. The treatment was not associated with any significant complications in either group. Trial registration: The trial was registered at clinical trials.gov under NCT04322500 on 25/03/2020 (“retrospectively registered”).

Conclusions: Modification of the intestinal microbiome with specific probiotics can alter the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis. Probiotic supplementation can increase the effectiveness of traditional therapies by prompting the complete resolution of chalaziosis in a shorter amount of time, in an easy and feasible way.

— Read on link.springer.com/article/10.1007/s00431-020-03880-5

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.